Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06914154 · ClinicalTrials.gov registry record
Emulation of the SUMMIT Heart Failure Trial in Healthcare Claims Data
A clinical trial, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- 11,265
- Enrollment target
NCT06914154: Completed study, sponsored by Brigham and Women's Hospital.
NCT06914154 is a clinical trial that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 11,265 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06914154 has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- 11,265 participants
- Enrollment target
Study Summary
Investigators are building an empirical evidence base for real-world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Primary Outcome
To evaluate the comparative effect of tirzepatide vs placebo (sitagliptin) on all-cause mortality or heart failure hospitalization in patients with heart failure with preserved ejection fraction when following the eligibility criteria of the SUMMIT trial.
Interventions
- DRUG Placebo
- DRUG Tirzepatide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11,265 participants |
| Start Date | 2025-01-14 |
| Est. Completion | 2025-06-01 |
What the finished NCT06914154 record still lists
NCT06914154 is an observational study that tracks outcomes without assigning an intervention. Its 11,265 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06914154 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06914154 about?
NCT06914154 is a clinical study titled "Emulation of the SUMMIT Heart Failure Trial in Healthcare Claims Data". Investigators are building an empirical evidence base for real-world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such s...
What is the current status of trial NCT06914154?
This trial is currently completed. The enrollment target is 11,265 participants. The study started on 2025-01-14. Estimated completion is 2025-06-01.
What interventions are being tested in trial NCT06914154?
The interventions under investigation include: Placebo (DRUG), Tirzepatide (DRUG).
Who is sponsoring clinical trial NCT06914154?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06677060 · 11,300 participants · Phase 3
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
- NCT06531824 · 11,000 participants · Phase 3
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
- NCT07136012 · 11,000 participants · Phase 3
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
- NCT07181109 · 11,000 participants · Phase 3
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI